Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CDC25C | P30307 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | BMP1 | P13497 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL992030 | 0.83 | KCNH2 (0.50) | KCNH2TSHRNR1D1MAPTSIGMAR1 | |
| SCHEMBL28826275 | 0.83 | ESRRG (0.38) | SIGMAR1 | |
| SCHEMBL5523203 | 0.82 | KCNH2 (0.43) | KCNH2TSHRNR1D1MAPTSIGMAR1 | |
| SCHEMBL6274443 | 0.81 | L3MBTL1 (0.44) | LMNA | |
| SCHEMBL16682344 | 0.81 | KCNH2 (0.53) | KCNH2TSHRNR1D1ALDH1A1LMNA | |
| SCHEMBL5523204 | 0.81 | KCNH2 (0.43) | KCNH2TSHRNR1D1MAPTALDH1A1 | |
| SCHEMBL19491362 | 0.80 | KCNH2 (0.52) | KCNH2TSHRNR1D1MAPTSIGMAR1 | |
| SCHEMBL15807642 | 0.79 | KCNH2 (0.47) | KCNH2TSHRNR1D1MAPTSIGMAR1 | |
| SCHEMBL5653544 | 0.78 | KCNH2 (0.45) | KCNH2TSHRNR1D1MAPTSIGMAR1 | |
| SCHEMBL16107590 | 0.78 | KCNH2 (0.50) | KCNH2TSHRNR1D1MAPTSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2967066-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Therapeutics Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014145068-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | AERPIO THERAPEUTICS INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-2624916-A2 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | Aerpio Therapeutics Inc. (US) | 2013-08-14 | — | — | EP | disclosed |
| WO-2012047966-A2 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | AKEBIA THERAPEUTICS INC. (US) | 2012-04-12 | — | — | WO | disclosed |
| EP-2041102-A2 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | The Procter & Gamble Company (US) | 2009-04-01 | — | — | EP | disclosed |
| EP-2038265-A2 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | The Procter and Gamble Company (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008002570-A2 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008002569-A2 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |